March 2019 FDA Recall Drug by Remedyrepack Inc. (D-1081-2019 - CGMP Deviations; Detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) - N-Methylnitrosobutyric acid (NMBA).)

This Class II drug recall was voluntarily initiated by Remedyrepack Inc. on March 14, 2019 for the product Drug. The FDA reported the reason for recall as cgmp deviations; detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (api) - n-methylnitrosobutyric acid (nmba).. The product was distributed in Product was distributed to one sole customer, Miami, FL. and the recall is currently terminated.

Recall Number: D-1081-2019

Reason for Recall
CGMP Deviations; Detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) - N-Methylnitrosobutyric acid (NMBA).
Initiated
03-14-2019
Reported
04-17-2019
Quantity
33 blister cards of 30 = 990 tablets

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Product was distributed to one sole customer, Miami, FL.
Losartan 50mg Tablet, 30 count each blister card.

Batch or Lot Expiration Information

Lot# 70518-0588-01
Lot# : J0328416-101518, Exp. Date: 10/2019